MedTrace Logo

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

NCT00051129 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 291

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).

Conditions

  • Macular Degeneration
  • Maculopathy, Age-Related
  • Age-Related Maculopathies
  • Age-Related Maculopathy
  • Maculopathies, Age-Related

Interventions

DRUG

Anecortave Acetate 15 mg sterile suspension

0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection

OTHER

Anecortave Acetate Vehicle

Administered as a posterior juxtascleral injection

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00051129 on ClinicalTrials.gov